ProRelease™ patent granted in Europe

Kuecept Ltd, a specialist drug delivery technology company based in the UK, is pleased to announce it has received confirmation that its ProRelease™ microparticle delivery system patent application has been granted in Europe.

The ProRelease™ delivery system is a multi-particulate solid intermediate that can be easily incorporated into conventional oral solid dosage formulations, including capsules and tablets and can be tailored to achieve specific drug release profiles, including modified, delayed and targeted release. The technology is particularly applicable to improve the bioavailability of poorly soluble basic compounds, as well as compounds that are pH labile, induce gastric irritancy or require site specific deliver to achieve maximum absorption. In addition, the technology offers additional benefits compared to current modified release dosage forms, including:

• Reduced variability of drug gastric emptying time
• No fed / fasted variability, lowering dependency on the nutrition state
• Lower intra- and inter-individual variability of dissolution of the drug substance
• Lower intra- and inter-individual variability of absorption of the drug substance into the systemic circulation
• Increased residence times within the lower intestine. Options for targeted delivery for localised dissolution to improve absorption and reduce dose

The ProRelease™ delivery system is already being evaluated by a number of major pharmaceutical companies worldwide for products entering clinical development, as well as compounds requiring reformulation or Life Cycle Management. If you would like more information on the technology or have any technical issues you would like to discuss, please contact us directly.